Last reviewed · How we verify

Placebo to montelukast chewable tablets

Organon and Co · FDA-approved active Small molecule

Placebo to montelukast chewable tablets is a Leukotriene receptor antagonist Small molecule drug developed by Organon and Co. It is currently FDA-approved for Asthma (prophylaxis and chronic treatment), Allergic rhinitis, Exercise-induced bronchoconstriction.

Montelukast is a leukotriene receptor antagonist that blocks cysteinyl leukotriene receptors to reduce airway inflammation and bronchoconstriction.

Montelukast is a leukotriene receptor antagonist that blocks cysteinyl leukotriene receptors to reduce airway inflammation and bronchoconstriction. Used for Asthma (prophylaxis and chronic treatment), Allergic rhinitis, Exercise-induced bronchoconstriction.

At a glance

Generic namePlacebo to montelukast chewable tablets
SponsorOrganon and Co
Drug classLeukotriene receptor antagonist
TargetCysLT1 receptor (cysteinyl leukotriene type-1 receptor)
ModalitySmall molecule
Therapeutic areaRespiratory / Immunology
PhaseFDA-approved

Mechanism of action

Montelukast selectively antagonizes cysteinyl leukotriene type-1 (CysLT1) receptors on airway smooth muscle and inflammatory cells. By blocking these receptors, it prevents the inflammatory cascade triggered by leukotrienes, which are potent mediators released during allergic and asthmatic responses. This reduces airway inflammation, mucus production, and bronchoconstriction.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebo to montelukast chewable tablets

What is Placebo to montelukast chewable tablets?

Placebo to montelukast chewable tablets is a Leukotriene receptor antagonist drug developed by Organon and Co, indicated for Asthma (prophylaxis and chronic treatment), Allergic rhinitis, Exercise-induced bronchoconstriction.

How does Placebo to montelukast chewable tablets work?

Montelukast is a leukotriene receptor antagonist that blocks cysteinyl leukotriene receptors to reduce airway inflammation and bronchoconstriction.

What is Placebo to montelukast chewable tablets used for?

Placebo to montelukast chewable tablets is indicated for Asthma (prophylaxis and chronic treatment), Allergic rhinitis, Exercise-induced bronchoconstriction.

Who makes Placebo to montelukast chewable tablets?

Placebo to montelukast chewable tablets is developed and marketed by Organon and Co (see full Organon and Co pipeline at /company/organon-and-co).

What drug class is Placebo to montelukast chewable tablets in?

Placebo to montelukast chewable tablets belongs to the Leukotriene receptor antagonist class. See all Leukotriene receptor antagonist drugs at /class/leukotriene-receptor-antagonist.

What development phase is Placebo to montelukast chewable tablets in?

Placebo to montelukast chewable tablets is FDA-approved (marketed).

What are the side effects of Placebo to montelukast chewable tablets?

Common side effects of Placebo to montelukast chewable tablets include Headache, Dizziness, Dyspepsia, Elevated liver enzymes, Neuropsychiatric events (rare).

What does Placebo to montelukast chewable tablets target?

Placebo to montelukast chewable tablets targets CysLT1 receptor (cysteinyl leukotriene type-1 receptor) and is a Leukotriene receptor antagonist.

Related